Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Enhertu Braced for Price Cuts as Chuikyo OKs CEA Results; Evrysdi Not Subject to Scheme
March 24, 2022
- Alexion’s Bleeding Antidote to Be Approved as Early as This Month
March 24, 2022
- Pfizer COVID Booster OK’ed for Ages 12-17, Comirnaty Label Revised
March 24, 2022
- Ensure Appropriate Care System for Post-COVID Vaccination Symptoms: MHLW Panels
March 23, 2022
- PMDA to Launch “GMP Roundtable” with Academia, Industry
March 23, 2022
- Kyowa Pharma to Face Biz Suspension Order over Manufacturing Flaws
March 23, 2022
- AMED’s SCARDA Boots Up as Command Tower for Vaccine Development
March 23, 2022
- MHLW to Order Label Revision for Somatropin, IFNβ-1a/1b Preparations
March 23, 2022
- Safety Panel OKs FY2022 Survey on US, EU Quality Control Systems, Questions Lagevrio Measures
March 22, 2022
- Conduct Yearly Surprise GMP Inspections for High-Risk Sites: MHLW
March 22, 2022
- Veklury Expands Label for Mild COVID-19
March 22, 2022
- MHLW Panel to Discuss Pfizer COVID Booster for Ages 12-17
March 18, 2022
- PM Vows Effective Supply Chain Surveys as Economic Security Bill Enters Diet
March 18, 2022
- MHLW to Ponder Integration of Drug Supply Info with Industry Input: Minister
March 17, 2022
- LDP Project Team to Discuss Fourth COVID Shot
March 17, 2022
- Japan to Secure Extra 3 Million Doses of COVID Drugs, 145 Million Vaccine Shots Too: PM
March 17, 2022
- Economic Security Bill to Enter Diet Deliberations on March 17
March 17, 2022
- Japan Approves Array of Fertility Treatments ahead of Coverage Rollout
March 16, 2022
- MHLW Orders Label Revisions for Brilinta, Ofev, Stocrin
March 16, 2022
- Japan to Ponder Drug Pricing that Ensures Domestic API Production: PM
March 15, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…